Search results
16 kwi 2022 · Groups led by peers with diabetes from neighbouring countries have been mobilising online to get donations of insulin and supplies for the Ukrainian population, but the uncertainty of how long this confrontation will last makes it difficult to estimate whether these efforts will be enough.
9 mar 2022 · In a country still struggling with the burden of the COVID-19 pandemic, the Russian invasion of Ukraine has further disrupted medical services, including diabetes care. 7·1% of the Ukrainian adult population lives with diabetes and non-communicable diseases are the leading case of premature death.
13 maj 2024 · Saxagliptin is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Saxagliptin is not for treating type 1 diabetes. Saxagliptin is sometimes used in combination with other diabetes medications. Saxagliptin may also be used for purposes not listed in this medication guide.
26 maj 2021 · An interactive map provides reliable diabetes data for each region of the country. The Atlas: Diabetes in Ukraine, developed by the Ukrainian Diabetes Federation, and supported by pharmaceutical company, Indar, will serve as a useful guide for decision-makers, healthcare professionals and PwD.
11 maj 2020 · To prevent diabetes complications and alleviate the financial burden of diabetes care on patients, the Ukrainian government reimburses diabetes medication and provides glucose monitoring, but there are significant gaps in the care continuum.
Type-2 diabetes mellitus (T2DM) is one of the leading causes of poor health and high health care expenditure in Ukraine. There are close to 3 million adults with diabetes and T2DM prevalence is at 8.4%.ii,iii This puts Ukraine into an average position across Eastern and Central European countries for T2DM prevalence (Figure 1).
Patients with type 2 diabetes mellitus are often initially treated with only diet and exercise. If those measures are not sufficient for glycemic control, patients may be prescribed non-insulin antihyperglycemic medications (eg, injectable glucagon-like peptide-1 [GLP-1] receptor agonists), insulin, or a combination of these medications.
